New Content  edit
Get The App!

Attend Free Live Webinars on WHO Group 3 Pulmonary Hypertension Patients

Attend Free Live Webinars on
WHO Group 3 Pulmonary
Hypertension Patients

New Live Webinars
Presented by Expert Faculty
Not available for CME/CE credit

Series Overview

WHO Group 3 pulmonary hypertension is a complex form
of pulmonary hypertension manifested as a varying
combination of hypoxia induced pulmonary
vasoconstriction and interstitial pulmonary fibrosis. These
programs examine the pathophysiology, epidemiology,
and diagnosis of Group 3 pulmonary hypertension. With
no currently approved medical therapies for Group 3 PH,
the data for and against use of Group 1 PAH medications
are considered with examples using patient case data.

 





Broadcast Schedule

No events currently scheduled.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Epidemiology and definitions of WHO Group 3 disease
  • Mechanism of disease and the link between hypoxia, parenchymal disease and PH
  • Clinical consequences of elevated pulmonary pressure and resistance in patients with WHO Group 3 disease
  • Screening, diagnosis, and treatment of WHO Group 3

Target Audience

These programs are designed to meet the educational needs of physicians, nurses, and other healthcare professionals involved in the care of pulmonary hypertension patients.

Fee Information

There is no fee for this educational activity

These activities are sponsored by United Therapeutics
Not available for CME/CE credit